GH, CARDIOVASCULAR RISK AND VISCERAL ADIPOSITY IN WOMEN

GH、女性心血管风险和内脏肥胖

• 批准号: 7731318
• 负责人: Karen K Miller
• 金额: $ 0.23万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731318
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Dose; Fatty acid glycerol esters; Funding; Grant; Hormone replacement therapy; Institution; Obesity; Population; Purpose; Recombinant Growth Hormone; Relative (related person); Research; Research Personnel; Resources; Risk Marker; Somatotropin; Source; Testing; United States National Institutes of Health; Visceral; Weight; Woman; cardiovascular risk factor; growth hormone deficiency; heart disease risk

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study examines women who have both high levels of belly fat and low levels of growth hormone (GH). The purpose of the study is to investigate whether GH replacement therapy reduces belly fat in this population. Since belly fat is associated with an increased risk for heart disease, we are also studying whether GH replacement therapy reduces the risk of heart disease in this population. Specific Aims - The following hypotheses will be tested: Specific Aim 1: Women with visceral adiposity have reduce growth hormone (GH) secretion, which is associated with increased cardiovascular risk. We will investigate in women with visceral adiposity whether: A. Growth hormone secretion is reduced compared with 1) normal-weight women and 2) BMI-matched women who do not have visceral adiposity b. Reduced growth hormone secretion is associated with increases in cardiovascular risk markers. Specific Aim 2: Administration of low dose recombinant GH for six months to women with visceral adiposity and relative growth hormone deficiency will result in reduced visceral fat mass and improvements in markers of cardiovascular risk.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究研究了既有高水平腹部脂肪又含量低的生长激素（GH）的女性。 该研究的目的是研究GH替代疗法是否减少了该人群中的腹部脂肪。 由于腹部脂肪与心脏病的风险增加有关，因此我们还研究GH替代疗法是否会降低该人群中心脏病的风险。 具体目的 - 将测试以下假设： 特定目的1：内脏肥胖的女性可以减少生长激素（GH）分泌，这与心血管风险增加有关。 我们将在内脏肥胖的女性中调查是否：是否： A.与1）不具有内脏肥胖的BMI匹配的女性相比，生长激素分泌减少了。 b。降低的生长激素分泌与心血管风险标记的增加有关。 具体目标2：给予肥胖和相对生长激素缺乏症的女性低剂量重组GH六个月，将导致内脏脂肪质量降低和心血管风险标记的改善。